Marijuana Could Break Your Heart—Literally
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Love smoking weed? Prepare to get your heart broken—literally.
A flood of recent studies have detailed the damage marijuana does to your mental health, bringing the risks a renewed level of media attention. Weed's linked to everything from psychosis to violent behavior to dementia.
But 2025 has been dominated by another piece of bad news about marijuana: that it's just as bad for your cardiac health as it is for your mental health.
Consider a meta-analysis from BMJ Heart which appeared just last month.
The authors examined dozens of studies on marijuana users and found a two-fold—yes, you read that right—risk of cardiovascular death corresponding to weed use, as well as a 29 percent higher risk of major cardiac events.
Many of America's policymakers and all its addiction profiteers keep insisting weed is safe, healthy, and natural. But the BMJ data are just the tip of the iceberg.
A May study from the University of California San Francisco found that marijuana was associated with vascular dysfunction in chronic users—regardless of whether they were smoking it or using edibles.
There's no cheat code, in other words, to get around the cardiac damage marijuana does. Gummies and candies won't save you.
March saw a meta-analysis come out from the Journal of the American College of Cardiology (JACC) on 12 studies examining more than 75 million cases to investigate heart attack risk in weed users.
The results? Users are 51 percent more likely than nonusers to have had a heart attack.
The bad news hasn't just been hitting in 2025, of course.
A 2024 American Heart Association study found that daily users had a 25 percent higher risk of heart attack and 42 percent higher risk of stroke compared to non-users and that more frequent use led to higher risk. Another JACC study, this one from 2023, showed users had a 34 percent greater risk of developing coronary artery disease.
And on and on and on.
LISBON, PORTUGAL - MAY 31: A participant shows marijuana buds in Jardim das Amoreiras before the start of a rally for the legalization and regulation of cannabis in Portugal on May 31, 2025, in Lisbon,...
LISBON, PORTUGAL - MAY 31: A participant shows marijuana buds in Jardim das Amoreiras before the start of a rally for the legalization and regulation of cannabis in Portugal on May 31, 2025, in Lisbon, Portugal. More
Horacio Villalobos/Corbis/Getty Images
It's great that all this information is increasingly breaking through into the mainstream. The more people who are aware of it, the better the public health outcomes will be for every American. That goes double given that the U.S. is facing a crisis of marijuana use among both the young and the old (for whom cardiac worries should be paramount).
But people who actually pay attention to the public-health dangers marijuana presents have been shouting about this from the rooftops for decades.
A 2001 study published in the American Heart Association journal found that in the hour after marijuana use, the risk of a myocardial infarction jumps by almost 400 percent.
Those data appeared almost a quarter-century ago.
How did this aspect of weed's general public-health effect ever pass under the radar at all—especially since American culture has become laser-focused on wellness in the interim?
How many lives have been lost, people injured, families sundered?
The fact that weed's heart dangers have ever been anything less than a national story is a testament to how successful the marijuana industry, its advocates in the media, and the politicians it's coopted have been at reputation management.
Luckily, the word now seems to be out. But we need to get louder. It's time for everyone to reckon with this reality.
That means a renewed and urgent focus on prevention from our policymakers—and remember, prevention needs to target both young and old.
It means energetic callouts from journalists whenever "weed equals wellness" claims start to bubble up.
It means parents letting their kids know that yes, marijuana can be deadly.
Everyone invested in promoting sane policy and saving public health needs to take this to heart.
Dr. Kevin Sabet is the president and CEO of Smart Approaches to Marijuana.
The views expressed in this article are the writer's own.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
Pharma's turbo spending spree on US manufacturing
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Investments in U.S. drug manufacturing are skyrocketing. Pharma giants everywhere have announced massive, multi-year deals to build and expand facilities across the country as several market factors make the U.S. a favorable destination for producing branded drugs. The looming threat of U.S. tariffs remains a motivator for companies from around the globe. Earlier this month, President Donald Trump said tariffs as high as 200% on pharma products would be introduced 'very soon.' Other industry shifts, including the growing GLP-1 market and the demand for skilled workers in pharma's tech-heavy manufacturing environment, are also tipping the scales toward the U.S. Amid the investment boom, tens of billions of dollars are pouring into manufacturing hubs like Raleigh, North Carolina, and generating thousands of job openings for engineers, R&D personnel, operations professionals and more. Here's a look at the latest companies to hop on the U.S. manufacturing bandwagon. AstraZeneca makes its largest-ever single facility investment AstraZeneca joined the $50 billion club this month when it announced a sprawling manufacturing and R&D investment in the U.S. The size of the investment matches the other leading pledges from pharma companies this year — including Roche, Johnson & Johnson and Eli Lilly — to each pump $50 billion or more into U.S. facilities. CEO Pascal Soroit acknowledged that tariffs played a part in the U.K.-based company's decision to pump up its U.S. operations in a recent interview with Fortune, but also noted that Europe is 'losing ground' as a drug production destination by focusing on 'social benefits and managing costs.' AstraZeneca's plan includes $4 billion for a drug substance facility in Virginia — its largest single-facility manufacturing investment in the world. But the $50 billion in funds will stretch across the country and include an R&D expansion in Maryland, a continuous manufacturing expansion in Indiana, a next-generation cell therapy facility in Texas, a 'state of the art' R&D center in Massachusetts' biotech hub at Kendall Square and more. The American market for drugs also plays a starring role in the company's broader ambitions. All told, AstraZeneca aims to boost its total revenue from the $54 billion-mark it hit in 2024 to over $80 billion by 2030 — half of which it expects to be generated in the U.S., the company said. Biogen pours more into North Carolina Biogen is broadening its manufacturing footprint in North Carolina. The company said it will invest $2 billion into two campuses in the state's Research Triangle Park, Biogen's current hub for manufacturing. The fresh funds will expand Biogen's capacity for multiple modalities, including antisense oligonucleotides, while modernizing its operations with automation and AI. Biogen is still working to move past its Aduhelm debacle. The Eisai-partnered Alzheimer's drug notched a historic approval in 2021 but was later pulled from the market amid cost and efficacy controversies. Its other Alzheimer's treatment Leqembi has had a stronger showing on the market and has steadily risen in sales since last year. But Biogen has also been in cost-cutting mode since 2023 and expects revenue to decline this year. Going forward, the company is leaning on its pipeline, including treatments for Dravet syndrome, a rare form of epilepsy, to set the stage for future growth. Its latest manufacturing investment adds to the $10 billion it has funneled into North Carolina since setting up shop at Research Triangle Park in 1995. Thermo Fisher snags Sanofi facility to boost fill-finish chops Thermo Fisher Scientific is expanding its production prowess with the help of a growing Sanofi partnership. The companies said this month that Thermo Fisher is snapping up a sterile, fill-finish manufacturing site from the French pharma for an undisclosed sum. The move comes amid higher-than-expected profit last quarter for Thermo Fisher, one of the pharma industry's key suppliers of clinical research services and equipment. The new digs will help Thermo Fisher 'strengthen' its U.S. manufacturing capabilities for the broader pharma industry, the company stated. The latest move is also a part of the four-year, $2 billion commitment to U.S. manufacturing Thermo Fisher announced in April. Recommended Reading Tracking a moving target: Drugmakers brace for a looming tariff impact
The Hill
an hour ago
- The Hill
GOP senators urge White House to release delayed NIH funding
Sen. Katie Britt (R-Ala.) and 13 other Senate Republicans are urging the Trump administration to release National Institutes of Health (NIH) funding that has been held up for months. The GOP senators warned in a letter to White House budget chief Russell Vought that the 'slow disbursement of funds' that Congress appropriated in March 'risks undermining critical research and the thousands of American jobs it supports.' 'Suspension of these appropriated funds — whether formally withheld or functionally delayed — could threaten Americans' ability to access better treatments and limit our nation's leadership in biomedical science,' the senators warned. 'It also risks inadvertently severing ongoing NIH-funded research prior to actionable results,' they wrote. The Trump administration suspended or cut many NIH research grants earlier this year in order to undertake a thorough review to ensure they complied with Trump's orders to end federal support for diversity, equity and inclusion (DEI) programs. A database set up by a Harvard University researcher estimated that by the end of May more than 2,100 NIH grants worth more than $9 billion had been cancelled. NIH Director Jay Bhattacharya told senators in March at his confirmation hearing that his agency would restart grant reviews but an analysis by STAT, a health care news site, last month found that NIH had made little progress in narrowing the funding gap created by the freeze on grant approvals. Now Republican senators are trying to ramp up pressure on the Office of Management and Budget. They told Vought that they share his commitment to ensuring NIH funds are 'used responsibly and not diverted to ideological or unaccountable programs.' But they also argued that starving the NIH of funding could inadvertently undermine trust in the agency. 'Withholding or suspending these funds would jeopardize that trust and hinder progress on critical health challenges facing our nation. Ultimately, this is about finding cures and seeing them through to fruition,' the senators wrote. 'We respectfully request that you ensure the timely release of all FY25 NIH appropriations in accordance with congressional intent,' they added. The other GOP signatories were Sens. John Boozman (Ark.), Shelley Moore Capito ( Bill Cassidy (La.), Susan Collins (Maine), Lindsey Graham (S.C.), David McCormick (Pa.), Mitch McConnell (Ky.), Jerry Moran (Kansas), Lisa Murkowski (Alaska), Thom Tillis (N.C.), Todd Young (Ind.), Dan Sullivan (Alaska) and Tim Scott (S.C.).
Newsweek
2 hours ago
- Newsweek
Warning About 'Unusual Fatigue' Extended for Millions
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Officials in Wisconsin extended an air quality advisory impacting millions through Friday night as smoke pollution reached levels considered unhealthy for sensitive groups. Breathing in the smoke could worsen preexisting health conditions or cause new issues. People were told to monitor themselves for symptoms such as unusual fatigue, as it could indicate a serious problem, specifically for those with heart conditions. Why It Matters Widespread air quality alerts and advisories were issued across the Upper Midwest on Thursday due to dense wildfire smoke drifting south from Canada. The fine particle pollution—PM2.5—reached levels classified as "Unhealthy for Sensitive Groups" (USG) or worse in numerous counties, prompting warnings from the Wisconsin Department of Natural Resources (DNR). The primary populations at risk include older adults, children, and those with existing heart or respiratory conditions. Officials emphasized that even brief exposure to air pollutants carried in wildfire smoke can lead to exacerbation of underlying medical problems, trigger new symptoms, or prompt emergency medical needs, particularly among vulnerable groups. A person wearing a face mask takes photos of the skyline as smoke from wildfires in Canada cause hazy conditions in New York City on June 7, 2023. A person wearing a face mask takes photos of the skyline as smoke from wildfires in Canada cause hazy conditions in New York City on June 7, 2023. Angela Weiss/Getty What To Know The alert took effect at 3 p.m. on Thursday afternoon and will remain in place at least through Friday night at 11 p.m. Nearly all of Wisconsin is currently under the advisory, except for the southwest part of the state. Dozens of counties in northern, central, and southeastern Wisconsin are affected. The advisory covered both rural and urban areas, including cities such as Milwaukee, Green Bay, and La Crosse. The DNR and National Weather Service (NWS) urged residents, especially those with asthma, heart disease, or other lung problems, to reschedule or move activities indoors to minimize exposure. Younger children, older adults, and anyone noticing symptoms such as coughing or unusual fatigue were also advised to limit outdoor activity and seek medical attention if necessary. A Wisconsin DNR spokesperson told Newsweek on Thursday that there have been 11 air quality alerts issued so far this year, nearly triple the number of such alerts issued in 2024, reflecting the increased scope and frequency of wildfire-driven smoke incidents across the Midwest this summer. However, 14 such alerts were issued in Wisconsin in 2023 as Canadian wildfire smoke descended across the U.S. that year. Prior to 2023, there were zero alerts in 2022, and six alerts in 2021. Air quality alerts were also issued in Minnesota and Michigan on Friday. What People Are Saying The Wisconsin DNR spokesperson told Newsweek: "Wildfires occur frequently in the US and Canada throughout the summer months, so we will continue watching for potential smoke impacts as long as there are active wildfires." An NWS air quality alert for Wisconsin: "Canadian wildfire smoke has entered northwest Wisconsin Thursday and will continue to move to the southeast through the remainder of the day. On Friday, smoke will begin moving south. Winds will begin turning southerly Friday night into Saturday, at which point the smoke will begin moving back north. It is possible that the advisory will need to be extended into Saturday for some areas of Wisconsin." What Happens Next The air quality alert was scheduled to last through Friday night, with the potential for extension or geographic adjustment based on updated data from air monitors and forecast models. Residents are encouraged to remain vigilant for updated alerts and to monitor their own health closely, especially individuals in higher-risk categories.
